James Sun1, Dung-Tsa Chen2, Jiannong Li2, Weihong Sun1, Sean J Yoder3, Tania E Mesa3, Marek Wloch4, Richard Roetzheim1, Christine Laronga1, M Catherine Lee5. 1. Department of Breast Oncology, Moffitt Cancer Center, Tampa, Florida. 2. Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida. 3. Molecular Genomics Core Facility, Moffitt Cancer Center, Tampa, Florida. 4. Tissue Core, Moffitt Cancer Center, Tampa, Florida. 5. Department of Breast Oncology, Moffitt Cancer Center, Tampa, Florida. Electronic address: Marie.Lee@moffitt.org.
Abstract
BACKGROUND: Breast cancer (BC) risk assessment models are statistical estimates based on patient characteristics. We developed a gene expression assay to assess BC risk using benign breast biopsy tissue. METHODS: A NanoString-based malignancy risk (MR) gene signature was validated for formalin-fixed paraffin-embedded (FFPE) tissue. It was applied to FFPE benign and BC specimens obtained from women who underwent breast biopsy, some of whom developed BC during follow-up to evaluate diagnostic capability of the MR signature. BC risk was calculated with MR score, Gail risk score, and both tests combined. Logistic regression and receiver operating characteristic curves were used to evaluate these 3 models. RESULTS: NanoString MR demonstrated concordance between fresh frozen and FFPE malignant samples (r = 0.99). Within the validation set, 563 women with benign breast biopsies from 2007 to 2011 were identified and followed for at least 5 y; 50 women developed BC (affected) within 5 y from biopsy. Three groups were compared: benign tissue from unaffected and affected patients and malignant tissue from affected patients. Kruskal-Wallis test suggested difference between the groups (P = 0.09) with trend in higher predicted MR score for benign tissue from affected patients before development of BC. Neither the MR signature nor Gail risk score were statistically different between affected and unaffected patients; combining both tests demonstrated best predictive value (AUC = 0.71). CONCLUSIONS: FFPE gene expression assays can be used to develop a predictive test for BC. Further investigation of the combined MR signature and Gail Model is required. Our assay was limited by scant cellularity of archived breast tissue.
BACKGROUND:Breast cancer (BC) risk assessment models are statistical estimates based on patient characteristics. We developed a gene expression assay to assess BC risk using benign breast biopsy tissue. METHODS: A NanoString-based malignancy risk (MR) gene signature was validated for formalin-fixed paraffin-embedded (FFPE) tissue. It was applied to FFPE benign and BC specimens obtained from women who underwent breast biopsy, some of whom developed BC during follow-up to evaluate diagnostic capability of the MR signature. BC risk was calculated with MR score, Gail risk score, and both tests combined. Logistic regression and receiver operating characteristic curves were used to evaluate these 3 models. RESULTS: NanoString MR demonstrated concordance between fresh frozen and FFPE malignant samples (r = 0.99). Within the validation set, 563 women with benign breast biopsies from 2007 to 2011 were identified and followed for at least 5 y; 50 women developed BC (affected) within 5 y from biopsy. Three groups were compared: benign tissue from unaffected and affected patients and malignant tissue from affected patients. Kruskal-Wallis test suggested difference between the groups (P = 0.09) with trend in higher predicted MR score for benign tissue from affected patients before development of BC. Neither the MR signature nor Gail risk score were statistically different between affected and unaffected patients; combining both tests demonstrated best predictive value (AUC = 0.71). CONCLUSIONS: FFPE gene expression assays can be used to develop a predictive test for BC. Further investigation of the combined MR signature and Gail Model is required. Our assay was limited by scant cellularity of archived breast tissue.
Authors: Jessica A Cintolo-Gonzalez; Danielle Braun; Amanda L Blackford; Emanuele Mazzola; Ahmet Acar; Jennifer K Plichta; Molly Griffin; Kevin S Hughes Journal: Breast Cancer Res Treat Date: 2017-04-25 Impact factor: 4.872
Authors: J P Costantino; M H Gail; D Pee; S Anderson; C K Redmond; J Benichou; H S Wieand Journal: J Natl Cancer Inst Date: 1999-09-15 Impact factor: 13.506
Authors: M H Gail; L A Brinton; D P Byar; D K Corle; S B Green; C Schairer; J J Mulvihill Journal: J Natl Cancer Inst Date: 1989-12-20 Impact factor: 13.506
Authors: D Shattuck-Eidens; A Oliphant; M McClure; C McBride; J Gupte; T Rubano; D Pruss; S V Tavtigian; D H Teng; N Adey; M Staebell; K Gumpper; R Lundstrom; M Hulick; M Kelly; J Holmen; B Lingenfelter; S Manley; F Fujimura; M Luce; B Ward; L Cannon-Albright; L Steele; K Offit; A Thomas Journal: JAMA Date: 1997-10-15 Impact factor: 56.272
Authors: Dung-Tsa Chen; Aejaz Nasir; Aedin Culhane; Chinnambally Venkataramu; William Fulp; Renee Rubio; Tao Wang; Deepak Agrawal; Susan M McCarthy; Mike Gruidl; Gregory Bloom; Tove Anderson; Joe White; John Quackenbush; Timothy Yeatman Journal: Breast Cancer Res Treat Date: 2009-03-06 Impact factor: 4.872
Authors: T S Frank; S A Manley; O I Olopade; S Cummings; J E Garber; B Bernhardt; K Antman; D Russo; M E Wood; L Mullineau; C Isaacs; B Peshkin; S Buys; V Venne; P T Rowley; S Loader; K Offit; M Robson; H Hampel; D Brener; E P Winer; S Clark; B Weber; L C Strong; A Thomas Journal: J Clin Oncol Date: 1998-07 Impact factor: 44.544
Authors: A C Antoniou; A P Cunningham; J Peto; D G Evans; F Lalloo; S A Narod; H A Risch; J E Eyfjord; J L Hopper; M C Southey; H Olsson; O Johannsson; A Borg; B Pasini; B Passini; P Radice; S Manoukian; D M Eccles; N Tang; E Olah; H Anton-Culver; E Warner; J Lubinski; J Gronwald; B Gorski; L Tryggvadottir; K Syrjakoski; O-P Kallioniemi; H Eerola; H Nevanlinna; P D P Pharoah; D F Easton Journal: Br J Cancer Date: 2008-03-18 Impact factor: 7.640
Authors: Ruben A L de Groen; Ronald van Eijk; Stefan Böhringer; Tom van Wezel; Richard Raghoo; Dina Ruano; Patty M Jansen; Inge Briaire-de Bruijn; Fleur A de Groot; Karin Kleiverda; Liane Te Boome; Valeska Terpstra; Henriette Levenga; Alina Nicolae; Eduardus F M Posthuma; Isabelle Focke-Snieders; Lizan Hardi; Wietske C E den Hartog; Lara H Bohmer; Pancras C W Hogendoorn; Anke van den Berg; Arjan Diepstra; Marcel Nijland; Pieternella J Lugtenburg; Marie José Kersten; Steven T Pals; Hendrik Veelken; Judith V M G Bovée; Arjen H G Cleven; Joost S P Vermaat Journal: Blood Adv Date: 2021-10-12